Centers | ||
|
|
|
Centre for Collaborative Drug Research | Drug Discovery Unit | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) |
The Centre for Collaborative Drug Research is a multidisciplinary initiative bringing together the Faculties of Medicine and Pharmacy at the University of Toronto, Canadas leading academic institution and largest research entity, and the Centre... |
The Drug Discovery Unit (DDU) is a fully integrated drug discovery group established to translate world-class biology research into novel drug targets and candidate drugs. Housed within purpose built facilities at the University of Dundee, the DDU... Read more |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Partnerships |
Events |
Jobs |
Sanford-Burnham Partners with Johnson and Johnson to Identify New Treatments for Neurological DisordersSanford-Burnham Medical Institute and Janssen a unit of Johnson and Johnson have entered into research and development partnership to identify novel targets and develop drugs to treat Alzheimer's disease and psychiatric disorders. This multi year... View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
